checkAd
    Startseite > Aktien > Mind Medicine (MindMed) > Nachrichten
    Mind Medicine (MindMed) Aktie
    9,1200
     
    USD
    -5,10 %
    -0,4900 USD
    Letzter Kurs 02:00:00 Nasdaq
    9,1200
     
    USD
    600 STK
    Geldkurs 09.05.24
    9,1600
     
    USD
    800 STK
    Briefkurs 09.05.24
    ISIN: CA60255C8850 · WKN: A3DR6E · SYM: MNMD · Kanada

    Neueste Nachrichten

    MindMed to Participate at May Investor Conferences
    09.05.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
    09.05.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    MindMed Reports First Quarter 2024 Financial Results and Business Updates
    08.05.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
    04.05.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
    02.05.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    MindMed to Present at Upcoming May Medical Conferences
    25.04.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    TOP-Performer!: 'Must have'! Psychedelika-Aktien gehören zu den Star-Performern in 2024! Jetzt zuschlagen!
    15.04.24 · Carsten Ringler · GF Global Cannabis Opportunity Fund EURAnzeige
    MindMed to Present at Upcoming April Medical Conferences
    02.04.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    MindMed Announces Voluntary Delisting from Cboe Canada
    01.04.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
    11.03.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement
    07.03.24 · Business Wire (engl.) · Mind Medicine (MindMed)
    MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
    07.03.24 · Business Wire (engl.) · Mind Medicine (MindMed)